| Name | Title | Contact Details |
|---|
XLI is a full service manufacturer of precision engineered mechanical components and complex electro-mechanical subassemblies for applications including motorized vehicles, firearms, security instrumentation and communications. XLI manufactures your product according to your specifications and delivery requirements on a repetitive, low volume production basis in our U. S. facilities. Our organization provides complete customer support from engineering to manufacturing to product testing, packaging and delivery to streamline your procurement effort and expense.
The RAMPF Group stands for engineering and chemical solutions and caters to the economic and ecological needs of industry. Our range of competences includes: 🧪 Production and recycling of materials for modeling, lightweight construction, bonding, and protection ⚙️ Technical production systems for precise, dynamic positioning and automation, as well as technologies for complex composite parts production 💡 Comprehensive range of solutions and services, particularly for innovative customer-specific requirements Please find our imprint here: https://www.rampf-group.com/de/impressum/ https://www.rampf-group.com/en/imprint/
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
storyoftheseason.com